Drug-Induced Uveitis: Causes, Symptoms, and Treatment

Higher doses, lower body weight, and taking multiple medications at the same time can all increase the likelihood of a reaction. Genetic factors also play a role. Specific genetic markers, including HLA-B27 and HLA-B51, are associated with a higher tendency toward inflammatory conditions and have been found in a meaningful portion of patients with fluoroquinolone-induced uveitis.

Drug-induced uveitis appears to affect women more often than men in certain medication categories. Reviews of fluoroquinolone-induced uveitis cases have found that the majority of affected patients are women, with a median age around 54. These patterns may reflect differences in how certain drugs are processed in the body.

Some medications show different rates of drug-induced uveitis among racial groups. Corticosteroid-related uveitis, for example, has been reported at a higher incidence in Black patients compared to white patients. The reasons are not entirely clear but may relate to differences in melanin content and how certain drugs interact with melanin inside the eye.

Certain medications carry well-established risks. The antiviral drug cidofovir causes nongranulomatous anterior uveitis (inflammation without certain cell clusters) in the large majority of patients who take it and can also cause abnormally low eye pressure. For rifabutin, risk is higher at doses of 600 mg or more per day, in patients with low body weight, and when certain other antibiotics or antivirals are taken at the same time.

The most important step is identifying and discontinuing the medication causing the reaction. In many cases, stopping the drug alone leads to resolution of the inflammation. If the medication is essential for treating another condition, a specialist will work with the prescribing physician to find an appropriate alternative. Drug-induced uveitis typically begins to resolve within weeks after the responsible medication is stopped.

For anterior uveitis caused by medications, corticosteroid eye drops (drops that reduce inflammation) are the standard treatment. Cycloplegic or mydriatic drops (which dilate the pupil and relax the focusing muscle of the eye) are often prescribed at the same time to reduce pain and prevent the iris from adhering to the lens. The frequency and tapering schedule for these drops will be guided by the severity of inflammation and the patient's response to treatment.

When inflammation is severe, involves the back of the eye, or does not respond to eye drops alone, oral or injectable corticosteroids may be needed. In rare cases where inflammation persists despite stopping the offending drug and completing steroid treatment, additional anti-inflammatory medications may be considered. The goal is always to control inflammation as quickly as possible to protect the retina and other structures inside the eye.

Some forms of drug-induced uveitis raise eye pressure, while others cause pressure that is abnormally low (a condition called hypotony). Both extremes can harm vision. A specialist will monitor eye pressure carefully throughout treatment and may prescribe pressure-lowering drops or adjust the treatment plan as needed.

Most reported cases involve prescription medications, but some over-the-counter products and supplements have been associated with rare cases of uveitis. If you develop eye pain, redness, or blurred vision after starting any new product, whether prescription, over-the-counter, or a supplement, that timing matters and should be reported to a specialist promptly. Do not stop a prescribed medication without speaking with your prescribing physician first.

In the vast majority of cases, treatment with corticosteroid and cycloplegic eye drops is temporary. Once the offending medication is stopped and inflammation resolves, drops are gradually tapered and then discontinued. Most patients do not require ongoing eye drop therapy after recovery, though follow-up visits are still important to confirm the inflammation has fully cleared.

This depends on the specific medication and drug class involved. In some cases, another drug within the same family may be well tolerated. In other cases, a cross-reaction is possible. A specialist and the prescribing physician should work together to carefully weigh the risks and benefits. If a switch is made, closer monitoring for eye symptoms is warranted, at least during the initial period of use.

The timing of symptoms in relation to starting a new medication is the strongest practical clue. Symptoms that appear days to weeks after beginning a new drug deserve a focused conversation with a specialist. That said, infections, autoimmune conditions, and other causes can produce identical symptoms, so only a proper eye examination and diagnostic workup can confirm the cause. Never assume the reason without a professional evaluation.

Sudden vision loss, a dramatic increase in floaters, flashes of light, or a shadow or curtain spreading across your vision require immediate evaluation at an emergency eye care facility. These symptoms can signal complications that threaten permanent vision loss if not addressed quickly. Eye pain, redness, and light sensitivity that develop after starting a new medication should also be assessed promptly, even if the symptoms seem mild at first.